Recognizing the Clinical Signals That Matter: Cellular Therapy Referral Awareness in Multiple Myeloma

Multiple myeloma is a heterogeneous, relapsing disease in which no single line of therapy is curative for most patients. As treatment goals have evolved—moving from disease control toward deep and durable remission—the care team’s understanding of disease trajectory, risk features, and response patterns has become increasingly important.^1,2 For the oncology care team, this clinical context shapes patient monitoring, multidisciplinary communication, and referral triggers. 

Clinical staging and risk assessment help contextualize disease trajectory, prognosis, and treatment planning. Familiarity with these concepts can support more informed care coordination, patient education, and recognition of when a patient’s clinical course may warrant multidisciplinary discussion. 

The International Staging System (ISS) and its revised version (R-ISS) use markers such as serum beta-2 microglobulin, albumin, lactate dehydrogenase, and cytogenetic risk to categorize disease burden and prognosis at diagnosis.^3,4 Beyond staging, the Mayo Stratification for Myeloma and Risk-Adapted Therapy (mSMART) framework helps identify patients whose disease biology makes early relapse and drug resistance more likely.⁵ High-risk cytogenetic features, including deletion 17p, translocations t(4;14) and t(14;16), and gain 1q, are associated with shorter remissions, more aggressive relapse patterns, and often less durable responses to conventional therapy.⁶ 

Importantly, not all myeloma is the same. A patient with high-risk cytogenetics who is progressing at 12 to 18 months represents a qualitatively different clinical situation than a standard-risk patient experiencing late relapse. Clinicians who understand this distinction can recalibrate their clinical vigilance accordingly, even if they are not independently ordering FISH cytogenetics or staging workups. 

Response depth also matters in this context. The International Myeloma Working Group (IMWG) recognizes depth and durability of response as meaningful treatment endpoints.⁷ Minimal residual disease (MRD) negativity, sustained over time, is increasingly associated with improved outcomes.⁸ For the care team, a patient who achieves only a partial response or who experiences early progression after responding may be communicating something important about disease biology that warrants multidisciplinary attention.

Historically, CAR T-cell therapy was reserved for patients who had exhausted multiple prior lines of therapy. However, clinical interest has grown around whether earlier consideration—particularly in patients with high-risk disease or early relapse—may yield better outcomes. The rationale is that patients with fewer prior lines of therapy may have healthier T-cells, less refractory disease, and better functional status at the time of cellular therapy evaluation, which may positively influence both efficacy and tolerability.⁹ 

This also underscores the importance of individualized assessment. Rather than applying a uniform pathway, the goal is to identify the right patients at the right time. This process involves more than counting prior lines of therapy; it requires attentiveness to individual disease biology, treatment history, and functional status. 

Recognizing when a patient’s disease course may warrant reassessment often begins before a formal progression assessment is documented. There are several practical patterns worth attention: 

• An M-protein or free light chain level that plateaus rather than continues to fall 
• A patient returning to the clinic earlier than expected with new bone pain, fatigue, or infection 
• Lab trends that fall outside the expected post-treatment pattern, such as rising creatinine, new anemia, or declining platelets 
• A patient who reports, “Something just feels different.”

These factors do not determine treatment choice on their own, but they may help the care team recognize when a patient’s disease course should be discussed in a multidisciplinary setting. Given that early relapse carries a distinctly poor prognosis and is recognized in the literature as a meaningful clinical trigger,^9,10 the conversation about evaluation for different treatment options, including cellular therapies, can start when these patterns emerge. 

Across the care team, members who see patients frequently and longitudinally are often the first to notice subtle shifts in patient status, such as new symptoms, changes in functional tolerance, or a patient’s own sense that something has changed.¹ Familiarity with baseline risk features, prior response patterns, and expected treatment trajectories supports timely communication with the treating physician. Reinforcing patient education on what to report and when is a meaningful contribution to early recognition of clinical change. 

Care team members who recognize suboptimal response, early progression, or emerging high-risk features are well positioned to raise the question in a multidisciplinary setting. Recognizing the pattern and surfacing it to the broader care team is a meaningful clinical contribution. 

Facilitating communication between referring and treating teams, accurately capturing treatment history, and ensuring logistical readiness for evaluation are equally important functions. Awareness of the clinical signals that may prompt referral discussions helps the broader team anticipate documentation needs, coordinate scheduling, and reduce delays that could affect patient access to timely evaluation. 

• Treatment goals have evolved toward depth and durability of response. Suboptimal response and early progression are important clinical signals. 
• Clinical staging and risk stratification, including mSMART, cytogenetic risk features, and IMWG response criteria, provide important context for prognosis, treatment planning, and care coordination in multiple myeloma. 
• There is growing clinical interest in earlier consideration of CAR T-cell therapy for patients with high-risk disease, limited prior therapy, and favorable functional reserve. 
• The oncology care team is often the first to recognize shifts in disease trajectory. That recognition is a meaningful contribution to multidisciplinary care. 
• Both clinical factors and logistical readiness shape referral awareness. Understanding the clinical context behind cellular therapy evaluation helps the care team support timely, informed multidisciplinary discussion. 

1. Beaupierre A, Lundberg R, Marrero L, Jain M, Wang T, Alencar MC. Management across settings: an ambulatory and community perspective for patients undergoing CAR T-cell therapy in multiple care settings. Clin J Oncol Nurs. 2019;23(2):27-34. 
2. Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. doi:10.1038/nrdp.2017.46. 
3. Greipp PR, San Miguel J, Durie BGM, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-3420. doi:10.1200/JCO.2005.04.242. 
4. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869. doi:10.1200/JCO.2015.61.2267. 
5. Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360-376. doi:10.1016/j.mayocp.2013.01.019. 
6. Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101-119. doi:10.1016/j.mayocp.2015.11.007. 
7. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548-567. doi:10.1002/ajh.25791. 
8. Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988-5999. doi:10.1182/bloodadvances.2020002827. 
9. Lahuerta JJ, Paiva B, Vidriales MB, Cordón L, Cedena MT, Puig N, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol. 2017;35(25):2900-2910. doi:10.1200/JCO.2016.69.2517. 
10. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79(7):867-874. doi:10.4065/79.7.867.